The history of “bad cholesterol” has had a checkered past. Bayer’s cholesterol-reducing blockbuster Baycol allegedly caused over 100 deaths. Bayer paid over $1 billion to settle the Baycol cases.
Now come Crestor and Zocor, two more widely prescribed prescription-strength drugs designed to lower “bad cholesterol”. Both drugs allegedly cause serious muscle and kidney problems, including the potentially fatal, muscle-destroying condition rhabdomyolysis. This blog post focuses on Zocor.
Zocor (simvastatin) is a statin drug used to treat a condition known as hypercholesterolemia (better known as high cholesterol) in people at risk of developing coronary artery disease.
Statins block the ability of the liver to produce cholesterol so that the body takes any cholesterol it needs from food. It all sounds good in theory.
Zocor’s big competitive advantage in the cholesterol drug wars? It was cheaper. A lot cheaper. The old, “you get what you pay for” cliché rarely applies to drugs. The price is usually arrived at through an amalgamation of factors that don’t involve comparative efficacy. But in this case, it might hold up: at least one study has found that 80mg of Zocor was not as effective at reducing heart risks compared to the same dose of Lipitor.
But let’s get back to the point. In 2010, 2.1 million people in the United States were prescribed Zocor at a dose of 80mg. This dosage is particularly effective, because it lowers LDL cholesterol by an additional 6% versus a 40mg dose. More drugs, more cholesterol reduction. This makes sense.
- A 2023 study published in JAMA found no evidence that Zocor, a popular cholesterol-lowering drug, has any effect in treating depression. Despite earlier smaller studies suggesting potential off-label use of the statin-based medication, the researchers observed no difference in outcomes between patients receiving a 20mg dose of Zocor and those receiving a placebo.